Medtech 360

December 2013

European Markets for Facial Injectables 2014


Although market growth was dampened due to tepid economic conditions, the European facial injectable market will expand at a moderate pace through 2022, fueled by high patient demand—particularly for volumizing dermal fillers—and economic recovery.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for facial injectables in five major markets in Europe–France, Germany, Italy, Spain, and the UK–with market projections 10 years into the future.

We have up-to-date reports on a wide range of medical device markets worldwide.

Questions Answered in This Report:

  *  Differing from the trend in the US, the dermal filler market is larger than the BTX space in Europe.

What factors have resulted in the greater popularity of dermal filler products in Europe?

How do usage preferences for these products vary across European countries?

Is this trend expected to change over the forecast period?

  *   Despite tepid economic conditions and a fragile recovery in parts of Europe, the European market for facial injectables experienced slight growth in 2013 and will expand moderately over the forecast period.

Which market segments have the most potential for growth?

Which countries will see the fastest market expansion? Where will growth be slowest?

Will strong market growth mainly benefit a single competitor or will it be advantageous for multiple companies?

  *   The UK market remains by far the largest market of all countries covered in this report.

What factors have contributed to the UK's larger facial injectable market?

How will recent legislation regarding the discontinuation of remote prescriptions and the possibility of reclassifying dermal fillers affect the market over the forecast period?


Geographies Covered: France, Germany, Italy, Spain, UK

Procedures and Products Covered: Our analysis uses the following breakdown of procedures and products in the market:

Product Type


Dermal Fillers




Notes: *Other dermal fillers include semipermanent and nonpermanent dermal fillers. Newer-generation PRP and collagen fillers are not included in market valuations because these new products have yet to make a substantial impact on the market.

Market Forecast Features: Based on primary research with industry professionals, we use our proprietary forecasting model to provide an in-depth examination of current and future trends in procedure volumes, unit sales, ASPs, and market values over a 10-year period (2012–2022).

Competitive Analysis: We provide a detailed analysis of the competitive landscape and market shares for leading competitors.


Giridhar Madhusudhan

John Fletcher
Veronica Ross
Jackie Tang, M.A.
Tiffanie Demone

Search Reports

Mentioned in this report:

  • aap Implantate
  • Adoderm
  • Aesthetic Factors
  • Allergan
  • Anika Therapeutics
  • AQTIS Medical
  • BeautyWorksWest
  • Biocompatibles
  • BioForm Medical
  • BioPolymer
  • Clarion Medical
  • Contura
  • Croma-Pharma
  • Daewoong Pharmaceutical
  • Dermik Laboratories
  • Dove Spa
  • Fibrocell Science
  • Fidia Farmaceutici
  • Galderma
  • Galway Natural Health
  • GlaxoSmithKline
  • Intercytex
  • Ipsen
  • Johnson & Johnson
  • Kaylight
  • Laboratoires CosmoScience
  • Laboratoires FILORGA
  • Laboratoires GenĂ©vrier
  • Laboratoires ORGÉV
  • Laboratoires Pierre Fabre
  • Laboratoires TEOXANE
  • Laboratoires VIVACY
  • LCA Pharmaceutical
  • LIBP
  • MD Skin Solutions
  • Medytox
  • Mentor
  • Merz Pharma
  • Polymekon
  • Prollenium Medical Technologies
  • Q-Med
  • Revance Therapeutics
  • Rofil Medical International
  • Sanofi
  • Sinclair IS Pharma
  • Solstice Neurosciences
  • S & V Technologies
  • US WorldMeds
  • Valeant Pharmaceuticals International
  • Zimmer MedizinSysteme
Decision Resources Group brands include: